# A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy

> **NCT05248334** · PHASE1 · UNKNOWN · sponsor: **Tianjin Medical University Eye Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Diabetic Retinopathy
- Postoperative Recurrent Vitreous Hemorrhage
- Pars Plana Vitrectomy
- Ranibizumab

## Interventions

- **DRUG:** Ranibizumab Injection
- **PROCEDURE:** PPV

## Key facts

- **NCT ID:** NCT05248334
- **Lead sponsor:** Tianjin Medical University Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-10
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248334, "A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05248334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*